Current Price Disclosure cycle – 2025 April
Page last updated: 20 December 2024
The 2025 April cycle has a data collection period of 1 April 2024 to 30 September 2024.
Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 12 November 2024.
The reduction day is 1 April 2025.
Responsible persons should ensure that their authorised representatives keep their details up to date via the Health Products Portal, and sign up to the PBS Newsletter.
Contents
- Outcomes of Price Disclosure calculations
- Indicative prices of brands scheduled for a price disclosure reduction
- Confirmed prices of brands scheduled for a price disclosure reduction
- Brand price reductions and savings to patients
Outcomes of Price Disclosure calculations
The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health and Aged Care. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).
The outcomes reflecting these determinations will be published on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their December 2024 PBS approved ex‑manufacturer price (AEMP) and the weighted average disclosed price (WADP) was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2024 will also take the reduction on 1 April 2025 under section 99ADHA of the Act.
Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The deadline to lodge a dispute is 14 January 2025.
A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices is presented in the table below.
Legal Instrument Drug |
Legal Instrument Form |
Legal Instrument MoA |
Brands of PI designated brands under 99ADHC (Y/N) |
Floor Price |
Price reduction applied in 2 previous cycles (Y/N) |
Average Unadjusted Price Reduction (UPR) exceeds 12.5% over 3 cycles (Y/N) |
December 2024 AEMP |
April 2025 AEMP |
Percentage difference between December 2024 and April 2025 AEMP (%) |
UPR threshold (%) |
Calculations based on: |
---|---|---|---|---|---|---|---|---|---|---|---|
Adalimumab |
Injection 20 mg in 0.4 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$309.45 |
$272.84 |
11.83% |
10% |
GWAPD |
Adalimumab |
Injection 40 mg in 0.4 mL pre-filled pen |
Injection |
N |
- |
- |
- |
$505.95 |
$444.17 |
12.21% |
10% |
GWAPD |
Atomoxetine |
Capsule 10 mg (as hydrochloride) |
Oral |
Y |
$28.68 |
N |
Y |
$28.68 |
$21.31 |
25.70% |
10% |
OWAPD |
Atomoxetine |
Capsule 100 mg (as hydrochloride) |
Oral |
Y |
$37.29 |
N |
Y |
$37.29 |
$27.71 |
25.69% |
10% |
OWAPD |
Atomoxetine |
Capsule 18 mg (as hydrochloride) |
Oral |
Y |
$28.68 |
N |
Y |
$28.68 |
$21.31 |
25.70% |
10% |
OWAPD |
Atomoxetine |
Capsule 25 mg (as hydrochloride) |
Oral |
Y |
$28.68 |
N |
Y |
$28.68 |
$21.31 |
25.70% |
10% |
OWAPD |
Atomoxetine |
Capsule 40 mg (as hydrochloride) |
Oral |
Y |
$28.68 |
N |
Y |
$28.68 |
$21.31 |
25.70% |
10% |
OWAPD |
Atomoxetine |
Capsule 60 mg (as hydrochloride) |
Oral |
Y |
$28.68 |
N |
Y |
$28.68 |
$21.31 |
25.70% |
10% |
OWAPD |
Atomoxetine |
Capsule 80 mg (as hydrochloride) |
Oral |
Y |
$37.29 |
N |
Y |
$37.29 |
$27.71 |
25.69% |
10% |
OWAPD |
Azacitidine |
Powder for injection 100 mg |
Injection |
Y |
$40.79 |
N |
Y |
$40.79 |
$25.69 |
37.02% |
30% |
OWAPD |
Bevacizumab |
Solution for I.V. infusion 100 mg in 4 mL |
Injection |
N |
- |
- |
- |
$61.77 |
$53.82 |
12.87% |
10% |
OWAPD |
Bevacizumab |
Solution for I.V. infusion 400 mg in 16 mL |
Injection |
N |
- |
- |
- |
$247.07 |
$215.28 |
12.87% |
10% |
OWAPD |
Bisacodyl |
Tablet 5 mg |
Oral |
Y |
$5.99 |
N |
N |
$5.99 |
$4.00 |
33.22% |
30% |
OWAPD |
Bortezomib |
Powder for injection 2.5 mg |
Injection |
N |
- |
- |
- |
$28.47 |
$24.92 |
12.47% |
10% |
GWAPD |
Bortezomib |
Powder for injection 3.5 mg |
Injection |
N |
- |
- |
- |
$39.85 |
$34.88 |
12.47% |
10% |
GWAPD |
Bortezomib |
Solution for injection 2.5 mg in 1 mL |
Injection |
N |
- |
- |
- |
$28.47 |
$24.92 |
12.47% |
10% |
GWAPD |
Bortezomib |
Solution for injection 3.5 mg in 1.4 mL |
Injection |
N |
- |
- |
- |
$39.85 |
$34.88 |
12.47% |
10% |
GWAPD |
Buprenorphine |
Transdermal patch 10 mg |
Transdermal |
N |
- |
- |
- |
$12.62 |
$10.87 |
13.87% |
10% |
GWAPD |
Buprenorphine |
Transdermal patch 15 mg |
Transdermal |
N |
- |
- |
- |
$16.04 |
$13.81 |
13.90% |
10% |
GWAPD |
Buprenorphine |
Transdermal patch 20 mg |
Transdermal |
N |
- |
- |
- |
$19.47 |
$16.77 |
13.87% |
10% |
GWAPD |
Buprenorphine |
Transdermal patch 25 mg |
Transdermal |
N |
- |
- |
- |
$22.71 |
$19.56 |
13.87% |
10% |
GWAPD |
Buprenorphine |
Transdermal patch 30 mg |
Transdermal |
N |
- |
- |
- |
$25.95 |
$22.35 |
13.87% |
10% |
GWAPD |
Buprenorphine |
Transdermal patch 40 mg |
Transdermal |
N |
- |
- |
- |
$32.45 |
$27.95 |
13.87% |
10% |
GWAPD |
Buprenorphine |
Transdermal patch 5 mg |
Transdermal |
N |
- |
- |
- |
$7.01 |
$6.04 |
13.84% |
10% |
GWAPD |
Carvedilol |
Tablet 12.5 mg |
Oral |
Y |
$5.05 |
N |
Y |
$5.05 |
$4.00 |
20.79% |
10% |
GWAPD |
Carvedilol |
Tablet 25 mg |
Oral |
Y |
$6.31 |
N |
Y |
$6.31 |
$4.79 |
24.09% |
10% |
GWAPD |
Carvedilol |
Tablet 6.25 mg |
Oral |
Y |
$4.04 |
N |
Y |
$4.04 |
$4.00 |
0.99% |
10% |
GWAPD |
Cinacalcet |
Tablet 30 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$23.72 |
$19.75 |
16.74% |
10% |
GWAPD |
Cinacalcet |
Tablet 60 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$47.44 |
$39.51 |
16.72% |
10% |
GWAPD |
Cinacalcet |
Tablet 90 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$71.16 |
$59.26 |
16.72% |
10% |
GWAPD |
Clomipramine |
Tablet containing clomipramine hydrochloride 25 mg |
Oral |
Y |
$5.52 |
N |
Y |
$5.52 |
$4.65 |
15.76% |
10% |
GWAPD |
Cyclophosphamide |
Powder for injection 1 g (anhydrous) |
Injection |
N |
- |
- |
- |
$18.59 |
$15.60 |
16.08% |
10% |
OWAPD |
Cyclophosphamide |
Powder for injection 2 g (anhydrous) |
Injection |
N |
- |
- |
- |
$37.18 |
$31.20 |
16.08% |
10% |
OWAPD |
Dabigatran etexilate |
Capsule 110 mg (as mesilate) |
Oral |
N |
- |
- |
- |
$6.19 |
$5.53 |
10.66% |
10% |
OWAPD |
Dabigatran etexilate |
Capsule 150 mg (as mesilate) |
Oral |
N |
- |
- |
- |
$36.88 |
$32.94 |
10.68% |
10% |
OWAPD |
Dasatinib |
Tablet 100 mg |
Oral |
N |
- |
- |
- |
$1,197.56 |
$1,019.07 |
14.90% |
10% |
OWAPD |
Dasatinib |
Tablet 20 mg |
Oral |
N |
- |
- |
- |
$727.08 |
$618.71 |
14.90% |
10% |
OWAPD |
Dasatinib |
Tablet 50 mg |
Oral |
N |
- |
- |
- |
$1,197.56 |
$1,019.07 |
14.90% |
10% |
OWAPD |
Dasatinib |
Tablet 70 mg |
Oral |
N |
- |
- |
- |
$1,482.66 |
$1,261.67 |
14.90% |
10% |
OWAPD |
Deferasirox |
Tablet 180 mg |
Oral |
N |
- |
- |
- |
$60.54 |
$29.02 |
52.06% |
10% |
GWAPD |
Deferasirox |
Tablet 360 mg |
Oral |
N |
- |
- |
- |
$121.09 |
$58.04 |
52.07% |
10% |
GWAPD |
Deferasirox |
Tablet 90 mg |
Oral |
N |
- |
- |
- |
$30.27 |
$14.51 |
52.06% |
10% |
GWAPD |
Enoxaparin |
Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$91.60 |
$71.24 |
22.23% |
10% |
GWAPD |
Enoxaparin |
Injection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$103.62 |
$80.59 |
22.23% |
10% |
GWAPD |
Enoxaparin |
Injection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$129.53 |
$100.74 |
22.23% |
10% |
GWAPD |
Enoxaparin |
Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$33.58 |
$26.12 |
22.22% |
10% |
GWAPD |
Enoxaparin |
Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$37.53 |
$29.19 |
22.22% |
10% |
GWAPD |
Enoxaparin |
Injection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$64.97 |
$50.53 |
22.23% |
10% |
GWAPD |
Enoxaparin |
Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$69.08 |
$53.72 |
22.24% |
10% |
GWAPD |
Erlotinib |
Tablet 100 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$460.68 |
$379.60 |
17.60% |
10% |
OWAPD |
Erlotinib |
Tablet 150 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$569.91 |
$469.61 |
17.60% |
10% |
OWAPD |
Erlotinib |
Tablet 25 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$126.93 |
$104.59 |
17.60% |
10% |
OWAPD |
Erythromycin |
Capsule 250 mg (containing enteric coated pellets) |
Oral |
N |
- |
- |
- |
$11.16 |
$9.33 |
16.40% |
10% |
OWAPD |
Esomeprazole and clarithromycin and amoxicillin |
Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate) |
Oral |
N |
- |
- |
- |
$23.65 |
$20.69 |
12.52% |
10% |
OWAPD |
Esomeprazole and clarithromycin and amoxicillin |
Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate) |
Oral |
N |
- |
- |
- |
$23.65 |
$20.69 |
12.52% |
10% |
OWAPD |
Exemestane |
Tablet 25 mg |
Oral |
Y |
$42.25 |
N |
Y |
$42.25 |
$35.19 |
16.71% |
10% |
GWAPD |
Ezetimibe and rosuvastatin |
Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) |
Oral |
N |
- |
- |
- |
$8.04 |
$7.11 |
11.57% |
10% |
GWAPD |
Ezetimibe and rosuvastatin |
Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) |
Oral |
N |
- |
- |
- |
$7.88 |
$6.96 |
11.68% |
10% |
GWAPD |
Ezetimibe and rosuvastatin |
Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) |
Oral |
N |
- |
- |
- |
$8.94 |
$7.90 |
11.63% |
10% |
GWAPD |
Fluticasone propionate with salmeterol |
Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses |
Inhalation by Mouth |
N |
- |
- |
- |
$27.07 |
$24.36 |
10.01% |
10% |
GWAPD |
Fluticasone propionate with salmeterol |
Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) |
Inhalation by Mouth |
N |
- |
- |
- |
$27.07 |
$24.36 |
10.01% |
10% |
GWAPD |
Fulvestrant |
Injection 250 mg in 5 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$164.59 |
$134.60 |
18.22% |
10% |
GWAPD |
Gabapentin |
Tablet 600 mg |
Oral |
Y |
$23.12 |
N |
Y |
$23.12 |
$19.16 |
17.13% |
10% |
GWAPD |
Ganirelix |
Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$24.77 |
$22.10 |
10.78% |
10% |
GWAPD |
Hydromorphone |
Injection containing hydromorphone hydrochloride 10 mg in 1 mL |
Injection |
N |
- |
- |
- |
$7.52 |
$5.97 |
20.61% |
10% |
OWAPD |
Hydromorphone |
Injection containing hydromorphone hydrochloride 2 mg in 1 mL |
Injection |
N |
- |
- |
- |
$5.64 |
$4.48 |
20.57% |
10% |
OWAPD |
Hydromorphone |
Tablet containing hydromorphone hydrochloride 2 mg |
Oral |
N |
- |
- |
- |
$6.13 |
$4.38 |
28.55% |
10% |
OWAPD |
Hydromorphone |
Tablet containing hydromorphone hydrochloride 4 mg |
Oral |
N |
- |
- |
- |
$8.24 |
$5.89 |
28.52% |
10% |
OWAPD |
Hydromorphone |
Tablet containing hydromorphone hydrochloride 8 mg |
Oral |
N |
- |
- |
- |
$16.06 |
$11.47 |
28.58% |
10% |
OWAPD |
Infliximab |
Solution for injection 120 mg in 1 mL pre-filled pen |
Injection |
Y |
$252.40 |
N |
Y |
$252.40 |
$226.30 |
10.34% |
10% |
GWAPD |
Lamotrigine |
Tablet 5 mg |
Oral |
Y |
$5.88 |
N |
Y |
$5.88 |
$4.79 |
18.54% |
10% |
GWAPD |
Lansoprazole |
Capsule 30 mg |
Oral |
Y |
$4.48 |
N |
Y |
$4.48 |
$4.00 |
10.71% |
10% |
GWAPD |
Lansoprazole |
Tablet 30 mg (orally disintegrating) |
Oral |
Y |
$4.48 |
N |
Y |
$4.48 |
$4.00 |
10.71% |
10% |
GWAPD |
Latanoprost with timolol |
Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL |
Application to the eye |
Y |
$7.58 |
N |
Y |
$7.58 |
$6.45 |
14.91% |
10% |
GWAPD |
Lenalidomide |
Capsule 10 mg |
Oral |
N |
- |
- |
- |
$669.88 |
$548.44 |
18.13% |
10% |
OWAPD |
Lenalidomide |
Capsule 15 mg |
Oral |
N |
- |
- |
- |
$806.80 |
$660.53 |
18.13% |
10% |
OWAPD |
Lenalidomide |
Capsule 25 mg |
Oral |
N |
- |
- |
- |
$1,055.57 |
$864.20 |
18.13% |
10% |
OWAPD |
Lenalidomide |
Capsule 5 mg |
Oral |
N |
- |
- |
- |
$511.34 |
$418.64 |
18.13% |
10% |
OWAPD |
Levodopa with carbidopa and entacapone |
Tablet 100 mg-25 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$67.44 |
$56.96 |
15.54% |
10% |
GWAPD |
Levodopa with carbidopa and entacapone |
Tablet 125 mg-31.25 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$70.00 |
$59.12 |
15.54% |
10% |
GWAPD |
Levodopa with carbidopa and entacapone |
Tablet 150 mg-37.5 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$73.82 |
$62.35 |
15.54% |
10% |
GWAPD |
Levodopa with carbidopa and entacapone |
Tablet 200 mg-50 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$79.69 |
$67.31 |
15.54% |
10% |
GWAPD |
Levodopa with carbidopa and entacapone |
Tablet 50 mg-12.5 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$61.06 |
$51.57 |
15.54% |
10% |
GWAPD |
Levodopa with carbidopa and entacapone |
Tablet 75 mg-18.75 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$63.86 |
$53.94 |
15.53% |
10% |
GWAPD |
Levothyroxine |
Tablet containing 100 micrograms anhydrous levothyroxine sodium |
Oral |
N |
- |
- |
- |
$9.73 |
$8.32 |
14.49% |
10% |
GWAPD |
Levothyroxine |
Tablet containing 125 micrograms anhydrous levothyroxine sodium |
Oral |
N |
- |
- |
- |
$12.49 |
$10.68 |
14.49% |
10% |
GWAPD |
Levothyroxine |
Tablet containing 200 micrograms anhydrous levothyroxine sodium |
Oral |
N |
- |
- |
- |
$11.41 |
$9.76 |
14.46% |
10% |
GWAPD |
Levothyroxine |
Tablet containing 50 micrograms anhydrous levothyroxine sodium |
Oral |
N |
- |
- |
- |
$9.39 |
$8.03 |
14.48% |
10% |
GWAPD |
Levothyroxine |
Tablet containing 75 micrograms anhydrous levothyroxine sodium |
Oral |
N |
- |
- |
- |
$9.55 |
$8.17 |
14.45% |
10% |
GWAPD |
Lurasidone |
Tablet containing lurasidone hydrochloride 40 mg |
Oral |
N |
- |
- |
- |
$18.99 |
$14.52 |
23.54% |
10% |
GWAPD |
Lurasidone |
Tablet containing lurasidone hydrochloride 80 mg |
Oral |
N |
- |
- |
- |
$37.97 |
$29.04 |
23.52% |
10% |
GWAPD |
Mefenamic acid |
Capsule 250 mg |
Oral |
N |
- |
- |
- |
$5.79 |
$4.56 |
21.24% |
10% |
GWAPD |
Metoclopramide |
Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL |
Injection |
Y |
$7.10 |
N |
Y |
$7.10 |
$6.17 |
13.10% |
10% |
OWAPD |
Morphine |
Injection containing morphine hydrochloride trihydrate 10 mg in 1 mL |
Injection |
N |
- |
- |
- |
$4.42 |
$3.85 |
12.90% |
10% |
OWAPD |
Morphine |
Injection containing morphine hydrochloride trihydrate 20 mg in 1 mL |
Injection |
N |
- |
- |
- |
$6.77 |
$5.89 |
13.00% |
10% |
OWAPD |
Morphine |
Injection containing morphine sulfate pentahydrate 10 mg in 1 mL |
Injection |
N |
- |
- |
- |
$4.61 |
$4.01 |
13.02% |
10% |
OWAPD |
Naltrexone |
Tablet containing naltrexone hydrochloride 50 mg |
Oral |
N |
- |
- |
- |
$85.54 |
$76.68 |
10.36% |
10% |
OWAPD |
Nebivolol |
Tablet 1.25 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$9.78 |
$8.59 |
12.17% |
10% |
GWAPD |
Nebivolol |
Tablet 10 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$27.60 |
$24.24 |
12.17% |
10% |
GWAPD |
Nebivolol |
Tablet 5 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$24.42 |
$21.44 |
12.20% |
10% |
GWAPD |
Norethisterone with ethinylestradiol |
Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets |
Oral |
N |
- |
- |
- |
$10.56 |
$5.56 |
47.35% |
10% |
OWAPD |
Norethisterone with ethinylestradiol |
Pack containing 21 tablets 500 micrograms-35 micrograms and 7 inert tablets |
Oral |
N |
- |
- |
- |
$10.56 |
$5.56 |
47.35% |
10% |
OWAPD |
Palonosetron |
Injection 250 micrograms (as hydrochloride) in 5 mL |
Injection |
N |
- |
- |
- |
$9.91 |
$6.80 |
31.38% |
10% |
OWAPD |
Perindopril |
Tablet containing perindopril arginine 10 mg |
Oral |
Y |
$4.07 |
N |
Y |
$4.07 |
$4.00 |
1.72% |
10% |
GWAPD |
Perindopril |
Tablet containing perindopril erbumine 8 mg |
Oral |
Y |
$4.07 |
N |
Y |
$4.07 |
$4.00 |
1.72% |
10% |
GWAPD |
Riluzole |
Oral suspension 50 mg per 10 mL, 300 mL |
Oral |
Y |
$87.29 |
N |
Y |
$87.29 |
$68.17 |
21.90% |
10% |
GWAPD |
Sildenafil |
Tablet 20 mg (as citrate) |
Oral |
Y |
$131.30 |
N |
Y |
$131.30 |
$95.81 |
27.03% |
10% |
GWAPD |
Sitagliptin |
Tablet 100 mg |
Oral |
N |
- |
- |
- |
$22.93 |
$19.33 |
15.70% |
10% |
OWAPD |
Sitagliptin |
Tablet 25 mg |
Oral |
N |
- |
- |
- |
$22.93 |
$19.33 |
15.70% |
10% |
OWAPD |
Sitagliptin |
Tablet 50 mg |
Oral |
N |
- |
- |
- |
$22.93 |
$19.33 |
15.70% |
10% |
OWAPD |
Sunitinib |
Capsule 12.5 mg |
Oral |
N |
- |
- |
- |
$581.73 |
$513.55 |
11.72% |
10% |
OWAPD |
Sunitinib |
Capsule 25 mg |
Oral |
N |
- |
- |
- |
$1,170.80 |
$1,033.58 |
11.72% |
10% |
OWAPD |
Sunitinib |
Capsule 37.5 mg |
Oral |
N |
- |
- |
- |
$1,754.71 |
$1,549.06 |
11.72% |
10% |
OWAPD |
Sunitinib |
Capsule 50 mg |
Oral |
N |
- |
- |
- |
$2,370.50 |
$2,092.68 |
11.72% |
10% |
OWAPD |
Tacrolimus |
Capsule 0.5 mg |
Oral |
Y |
$63.14 |
N |
Y |
$63.14 |
$51.48 |
18.47% |
10% |
GWAPD |
Tacrolimus |
Capsule 1 mg |
Oral |
Y |
$126.29 |
N |
Y |
$126.29 |
$102.96 |
18.47% |
10% |
GWAPD |
Tacrolimus |
Capsule 1 mg (once daily prolonged release) |
Oral |
Y |
$75.78 |
N |
Y |
$75.78 |
$61.78 |
18.47% |
10% |
GWAPD |
Tacrolimus |
Capsule 2 mg |
Oral |
Y |
$287.81 |
N |
Y |
$287.81 |
$234.65 |
18.47% |
10% |
GWAPD |
Tacrolimus |
Capsule 5 mg |
Oral |
Y |
$315.57 |
N |
Y |
$315.57 |
$257.28 |
18.47% |
10% |
GWAPD |
Tenofovir |
Tablet containing tenofovir disoproxil fumarate 300 mg |
Oral |
Y |
$77.46 |
N |
Y |
$77.46 |
$53.49 |
30.95% |
30% |
GWAPD |
Tobramycin |
Solution for inhalation 300 mg in 5 mL |
Inhalation |
Y |
$416.76 |
N |
Y |
$416.76 |
$322.41 |
22.64% |
10% |
GWAPD |
Trastuzumab |
Powder for I.V. infusion 150 mg |
Injection |
Y |
$123.75 |
N |
Y |
$123.75 |
$106.57 |
13.88% |
10% |
OWAPD |
Trastuzumab |
Powder for I.V. infusion 420 mg |
Injection |
Y |
$346.50 |
N |
Y |
$346.50 |
$298.41 |
13.88% |
10% |
OWAPD |
Trastuzumab |
Powder for I.V. infusion 440 mg with diluent |
Injection |
Y |
$320.29 |
N |
Y |
$320.29 |
$275.83 |
13.88% |
10% |
OWAPD |
Trastuzumab |
Powder for I.V. infusion 60 mg |
Injection |
Y |
$58.09 |
N |
Y |
$58.09 |
$50.03 |
13.88% |
10% |
OWAPD |
Vancomycin |
Capsule 125 mg (125,000 I.U.) (as hydrochloride) |
Oral |
N |
- |
- |
- |
$50.69 |
$44.16 |
12.88% |
10% |
GWAPD |
Vancomycin |
Capsule 250 mg (250,000 I.U.) (as hydrochloride) |
Oral |
N |
- |
- |
- |
$101.36 |
$88.30 |
12.88% |
10% |
GWAPD |
Varenicline |
Box containing 11 tablets 0.5 mg and 42 tablets 1 mg |
Oral |
N |
- |
- |
- |
$51.66 |
$45.35 |
12.21% |
10% |
OWAPD |
Varenicline |
Tablet 1 mg |
Oral |
N |
- |
- |
- |
$60.90 |
$53.46 |
12.22% |
10% |
OWAPD |
Flow-on price disclosure reductions
A list of brands of pharmaceutical items that will be subject to an automatic flow-on price disclosure reduction under section 99ADHB of the National Health Act 1953 on 1 April 2025 is available in the Pricing-Combination-Flow-on-Price-Reductions-FED-1-Apr-2025 (Excel 12KB). Sponsors are able to apply for Ministerial discretion for these reductions to be reduced or not apply. For more information see Ministerial Discretion.
Indicative prices of brands scheduled for a price disclosure reduction
The indicative prices for brands scheduled for price disclosure reductions in this cycle will be published to assist responsible persons and other stakeholders.
Indicative prices are not published for any medicines that are:
- not taking a price disclosure reduction in this cycle;
- new brands after the date of publication;
- brands with other price changes on the reduction day.
The indicative prices report will be published in January 2025.
Confirmed prices of brands scheduled for a price disclosure reduction
The Confirmed Prices Report outlines the approved ex‑manufacturer prices for brands scheduled to take a price disclosure reduction.
The confirmed prices report will be published in March 2025.
Brand price reductions and savings to patients
The Brand Price Reductions and Savings to Patients Report outlines the price disclosure reductions per brand and potential savings to non-concessional patients from 1 April 2025. This information is made available to assist patients understand how much they may save on their PBS medicines.
The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day.
The brand price reductions report will be published in March 2025.